Thanks for your fast reply. Also on their web-site, on the same page they talk about BIOD-123 and BIOD-125, which seem to have more promise of being viable.
In the Phase 1 clinical trial, absorption rates of BIOD-123 and BIOD-125 were significantly faster than that of Humalog® as indicated by 64% and 54% reductions, respectively, in mean times to half maximal insulin concentrations (p < 0.001 for both BIOD-123 and BIOD-125 compared to Humalog®). Both RHI-based formulations and Humalog®were well tolerated, with injection site tolerability generally perceived by patients to be similar to that of their usual mealtime injections used at home.
